Overview

Fiducial Markers Market is predicted to value over CAGR of over 4.3% during the forecast period 2022 to 2028.

Soaring funds, grants and investments by private and public organizations for research based on cancer, advancements in technology and rising acceptance of radiotherapy for oncological treatments are some of the key factors driving the growth of the market.
The fiducial markers are used for accurately locating the tumor to provide the radiation dosage during the process of radiotherapy. Technological advancements in developing novel navigational systems for accurate product placement has boosted the fiducial markers market growth. For example, Veran Medical Technologies has developed an advanced navigational system, SPiN System, that helps in locating the target so that the fiducial market is placed appropriately for resection or radiation. This technology also offers a three-dimensional view of fiducials that shall help in generating the report for accurate treatment and diagnosis. Increasing awareness regarding radiotherapy methods like intensity modulated radiotherapy, stereotactic radiosurgery and image-guided radiotherapy is predicted to increase the acceptance of fiducial markers.
The radiotherapy is highly preferred over chemotherapy considering the adverse side effects and complications related to targeted drug therapy and chemotherapy, thereby increasing the fiducial markers market demand throughout the forecast period. Radiotherapy is highly recommended for other cancer types as well. For example, in the stage 1 and stage 2 of the breast cancer, the patients are mainly prescribed with radiotherapy sessions and breast-conserving surgery. Conversely, the product implantation procedure is quite complex which might impede the adoption of these markers, thereby restraining the growth of the market. Furthermore, according to the NCBI, patients who underwent with the procedure of inserting transrectal fiducial markers for prostate cancer therapy of image guiding were diagnosed with haematospermia rectal bleeding, dysuria and haematuria which shall impede the proliferation of the market.

Market Segmentation:

By Product
• Metal-based Markers
o Pure Gold
o Gold Alloys
o Other Metal-based Markers
• Polymer-based Markers
• Other Fiducial Markers
By Modality
• CT/CBCT
• MRI
• Ultrasound
• X-Ray
By Application
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Head and Neck Cancer
• Others
By End User
• Hospitals
• Radiotherapy Center
• Academic and Research Center
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

The market is classified into product, modality, application, end user and region. The product segment is categorised into gold combination, polymer, liquid and other metals. The gold segment is predicted to hold the largest fiducial markers market share due to its superior stability and accurate visibility of these products with multiple modalities. Gold fiducial markers, along with the combination of other metals like platinum, nickel and titanium for enhancing their efficiency in visualising the tumors. For example, the gold fiducial markers, in combination with titanium stripes enhance the MRI image visibility. Multiple companies are heavily investing in research and development for designing products with improvements in efficiency. For example, IBA Dosimetry GmbH has announced a pure gold fiducial marker by the name Visicoil which is a helically shaped product that has a hollow core thereby reducing the prevalence of general complications like marker artifacts and migration. The modality segment is categorised into ultrasound, CT/CBCT, MRI and X-ray. The CT/CBCT segment is anticipated to lead the market owing to its ease of integration with current radiotherapy equipment and a low-level dosage exposure shall augment the growth of the segment. The ultrasound modality is predicted to grow at a substantial rate during the forecasted timeframe. This modality has a lower radiation toxicity as compared to other imaging modalities is a crucial factor for the proliferation of the market.
The application segment is categorised into prostate, breast and lung cancer. The prostate cancer segment is predicted to lead the market owing to the rising acceptance of prostate cancer treatment across the world. Increased prevalence of lung cancer and advancements in technology for developing enhanced fiducial markers for an effective treatment of the disease. The end user segment is divided into radiotherapy centres, hospitals and academic research centres. The hospitals segment is anticipated to lead the market owing to the availability of novel radiotherapy equipment in healthcare institutes and rise in the number of multispecialty hospitals.

Regional Analysis:

The North America region is expected to dominate the market owing to improvements in the reimbursement policies, an impounding presence of key market players and rise in the number of awareness initiatives undertaken by government bodies. Furthermore, increased acceptance of novel imaging modalities and radiotherapy procedures shall propel the growth of the market.

Competitive Landscape:

Some of the crucial market players associated are CIVCO Radiotherapy, IZI Medical Products, Naslund Medical AB, Medtronic PLC, QlRad Inc., QFIX, Boston Scientific Corp., Nanovi A/S, Eckert & Ziegler, IBA Dosimetry GmbH.

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key market trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the global fiducial markers market by product, by modality, by application, by end user and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•   We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•   The customization Mobility Care offered are free of charge with purchase of any license of the report
•   You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com